



---

E-Scape Bio Inc., a US based biotech focused on new therapeutics for genetic neurodegenerative diseases, is rapidly progressing a new therapeutic (ESB1609). The drug is given orally and works through a novel mechanism that induces the synthesis of certain proteins in the brain that may resolve the cholesterol imbalance in the brain in NPC-1 and reduce storage of lipids that cause neurodegeneration in NPC-1 as well as other lysosomal storage disorders. The company will provide ongoing updates early next year.

---

[www.e-scapebio.com](http://www.e-scapebio.com)